LRRC8A and metabolic disease: Tissue-specific ablation of LRRC8A impairs insulin signaling in adipose, skeletal muscle, and endothelial cells and disrupts insulin secretion from pancreatic β-cells, ultimately compromising glucose homeostasis.69, 70, 71 This dysregulation possibly leads to metabolic disorders, increasing the risk of type 2 diabetes.